Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
4
×
boston blog main
boston top stories
life sciences
national blog main
national top stories
4
×
clinical trials
new york blog main
san francisco blog main
third rock ventures
ally bridge group
antisense oligonucleotide
astellas pharma
atlas venture
audentes therapeutics
avapritinib
avidity biosciences
benzodiazepines
big data analytics
biogen
blackrock
blackstone group
blackstone life sciences
bluebird bio
blueprint medicines
cancer
cancer drugs
capmatinib
casdin capital
columbia university
david goldstein
depression
diabetic nephropathy
duchenne muscular dystrophy
dyne therapeutics
eli lilly
epi4k
epilepsy
essential tremor
What
genetic
4
×
medicines
drug
diseases
ipo
new
address
ago
aims
analysis
approval
approves
backed
bio
biotech
biotechs
blueprint
bring
cancer
carries
cause
ceo
certain
company
considering
data
designed
develop
drugs
dyne
early
employing
epilepsy
expected
experimental
eyes
fda
genes
goldfinch
having
Language
unset
Current search:
boston
×
genetic
×
" national top stories "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs